Atlas Trials

A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma

Clinical trial NCT07599371 · RECRUITING

Trial details

NCT number
NCT07599371
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Glioma
Start date
2024-10-10
Primary completion
2027-10-10
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.